EKF Diagnostics Holdings plc (EKDHF)

Market Cap	140.17M -4.0%
Revenue (ttm)	68.14M +2.3%
Net Income	3.31M -59.2%
EPS	0.01 -57.9%
Shares Out	n/a
PE Ratio	43.00
Forward PE	15.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Open	0.3289
Previous Close	0.2932
Day's Range	0.3289 - 0.3289
52-Week Range	0.2932 - 0.3552
Beta	0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 308
• Stock Exchange: OTCMKTS
• Ticker Symbol: EKDHF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error